(O-15) HPV infection and genotype distribution among male patients attending a sexual health clinic in Lima from 2024 to 2025

Abstract Introduction Human papillomavirus (HPV) is a serious global public health problem due to its high prevalence and its association with several types of malignancy. Research and prevention initiatives have focused on women, but it is scarce in men. Objetive Determine the prevalence and genotypic distribution of HPV in sexually active men in Lima, Peru. Methods Data from male patients who attended a private sexual health clinic and underwent HPV genotype testing between August 2024 and May 2025 was analyzed. The positivity to HPV testing (abbrev. “HPV+”) and the distribution of HPV genotypes were reported according to single high-risk genotypes (HR-HPV), single low-risk genotypes (LR-HPV), and mixed genotypes (mixed-HPV, includes any combination of HR-HPV and LR-HPV) by age group, diagnosis of genital warts and HPV vaccination status (patients were vaccinated after the consultation). Results A total of 730 patients attended consultations during the study period. The overall HPV positivity rate was 67.4%. Of HPV+ patients, 35.77% presented with mixed-HPV (most common combination: 59 and 6), 52.03%, and 12.20% for LR-HPV and HR-HPV, respectively. Individuals aged ≤30 years made up 40.24% of the total positive cases, followed by the 31-40 age group (35.57%). In HR-HPV, most common genotypes included 52(22.03%), 59(18.64%), 51(18.22%), and 16(16.95%). In LR-HPV, 6(53.24%), 43(21.53%), 11(18.98%), and 62/81 (17.82%%) were the most common genotypes. HPV+ among patients with warts was 71.98% (56.44% in patients without warts). In patients with warts, 10.27% and 37.84% presented HR-HPV and mixed-HPV, respectively. The 40.24% of HPV+ patients decided not to receive HPV vaccination (HR-HPV: 11.62%; mixed-HPV: 37.37%), while 8.32% completed the vaccination schedule (HR-HPV: 12.5%; mixed-HPV: 25%). Conclusions Seven out of 10 patients were HPV+. Among the 35 genotypes examined, HPV52 was the most prevalent in positive cases, followed by low-risk HPV6. Financing InSalud.